Clinical trials: Child-Pugh A Hepatocellular Carcinoma
Solid Tumour, Advanced Solid Malignancies
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in…
- Conditions
- Solid Tumour, Advanced Solid Malignancies, Child-Pugh A to B7 Advanced Hepatocellular Carcinoma, EGFR and/or ROS Mutant NSCLC
- Trial name
- NCT01219543
- Testing
- AZD1480 Daily, AZD1480 BID
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Liver Cancer
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
RATIONALE: Sorafenib tosylate and pravastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01075555
- Testing
- pravastatin sodium, sorafenib tosylate
- Where
- France
- Volunteers
- 323 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma, Cirrhosis
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
The purpose of this study is to test the safety and determine the maximum safe dose of an experimental drug called LDE225 (hedgehog inhibitor) in people with liver cancer.
- Trial name
- NCT02151864
- Testing
- LDE225
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jason K. Sicklick, M.D.
Hepatocellular Carcinoma (HCC), Second Line Treatment
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Open-label, single arm, multicenter phase II trial assessing the tolerability of a reduced starting dose of 40 mg cabozantinib for 4 weeks and subsequent dose escalation to 60 mg cabozantinib until disease progression or…
- Trial name
- NCT04522908
- Testing
- Cabozantinib Oral Tablet
- Where
- 10 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy. (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the…
- Conditions
- HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma, Liver Cancer
- Trial name
- NCT02989870
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Sorafenib, Bavituximab
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Rupture, Spontaneous, Rupture Liver
A Comparison Between Child-Pugh and Albumin-Bilirubin Scores
To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma
- Conditions
- Rupture, Spontaneous, Rupture Liver, Hepatocellular Carcinoma, Hepatic Impairment
- Trial name
- NCT03534843
- Testing
- Liver resection, Transcatheter arterial embolization
- Volunteers
- 230 people
- Sponsor
- Huazhong University of Science and Technology
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable…
- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
- Trial name
- GDFATHERHCC01 (NCT07219459)
- Testing
- Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 104 people
- Sponsor
- CatalYm GmbH
Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma.
- Trial name
- NCT01839604
- Testing
- AZD9150
- Where
- 7 sites in Hong Kong, Japan and 2 more
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Carcinoma, Hepatocellular
c-Met Second-Line Hepatocellular Carcinoma
This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A…
- Trial name
- NCT02115373
- Testing
- Tepotinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatocellular Carcinoma
Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is being developed for the treatment of inoperable HCC, using a platform technology known as HepDirectTM, which enables drugs to be targeted…
- Trial name
- NCT00073736
- Testing
- MB07133 300mg/m2/day, MB07133 600 mg/m2/day, MB07133 1200 mg/m2/day
- Where
- 4 sites in United States, Hong Kong and 1 more
- Volunteers
- 28 people
- Sponsor
- Ligand Pharmaceuticals
Child-Pugh Class A, Child-Pugh Class B
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies stereotactic body radiation therapy (SBRT) and transarterial chemoembolization (TACE) in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma
- Trial name
- NCT02507765
- Testing
- Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hepatocellular Carcinoma (HCC)
Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)
The goal of this clinical trial is to learn if lenvatinib or regorafenib can help treat people with advanced liver cancer (hepatocellular carcinoma, HCC) that cannot be removed with surgery after first treatment with…
- Trial name
- REVIVE (NCT07495579)
- Testing
- Lenvatinib, regorafenib
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma (HCC)
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- NCT06487559
- Testing
- Livmoniplimab, Budigalimab
- Where
- 11 sites in China
- Volunteers
- 3 people
- Sponsor
- AbbVie
Child-Pugh Class A, Child-Pugh Class B
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer…
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT02762266
- Testing
- Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent
- Where
- 2 sites in United States, Japan
- Volunteers
- 13 people
- Sponsor
- Stanford University
Carcinoma, Hepatocellular
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line treatment versus sorafenib in subjects…
- Trial name
- NCT01988493
- Testing
- Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 117 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Carcinoma, Therapy
Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
The hypothesis of this study is that the median time to progression in the experimental arm is 2 months as compared to the placebo arm of 1.4 months
- Trial name
- NCT01097083
- Testing
- Coriolus Versicolor
- Where
- 3 sites in Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Advanced Hepatocellular Carcinoma
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment
This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.
- Trial name
- FINELAND (NCT07297654)
- Testing
- Lenvatinib
- Volunteers
- 50 people
- Sponsor
- National Cancer Center, Korea
Child-Pugh A Hepatocellular Carcinoma
Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
Principal objective: to evaluate the effect of the combination pravastatin - sorafenib versus sorafenib alone on overall survival in patients with hepatocellular carcinoma developing on Child-Pugh A cirrhosis who are unsuitable…
- Trial name
- NCT01903694
- Testing
- Sorafenib + Pravastatin, Sorafenib
- Where
- France
- Volunteers
- 474 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hepatocellular Carcinoma, Cirrhosis
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy.
- Trial name
- NCT06007846
- Testing
- Namenda
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inova Health Care Services
Hepatocellular Carcinoma by BCLC Stage
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
Liver cancer is the third leading cause of cancer-related deaths worldwide. The majority of primary liver cancers occur as hepatocellular carcinoma (HCC), the incidence of which is increasing in many parts of the world.
- Trial name
- HESTIA (NCT05622071)
- Testing
- Tislelizumab
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- UNICANCER